Phreesia (NYSE:PHR) Issues Quarterly Earnings Results, Beats Estimates By $0.08 EPS

Phreesia (NYSE:PHR) released its earnings results on Wednesday. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.08, Zacks reports. Phreesia had a negative net margin of 20.43% and a negative return on equity of 32.78%. Phreesia updated its FY 2026 guidance to EPS.

Phreesia Stock Up 3.1 %

PHR stock traded up $0.72 during trading on Wednesday, reaching $23.95. The stock had a trading volume of 833,076 shares, compared to its average volume of 408,588. The company has a current ratio of 1.74, a quick ratio of 1.74 and a debt-to-equity ratio of 0.04. The firm has a fifty day moving average price of $27.34 and a 200 day moving average price of $23.99. The company has a market capitalization of $1.39 billion, a P/E ratio of -16.29 and a beta of 1.03. Phreesia has a 1-year low of $17.07 and a 1-year high of $30.53.

Wall Street Analyst Weigh In

Several analysts have commented on PHR shares. Citigroup lifted their target price on shares of Phreesia from $31.00 to $35.00 and gave the stock a “buy” rating in a research note on Friday, January 10th. Robert W. Baird dropped their target price on Phreesia from $34.00 to $30.00 and set an “outperform” rating for the company in a research note on Wednesday, December 11th. KeyCorp increased their target price on Phreesia from $28.00 to $30.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 8th. Truist Financial lifted their price target on Phreesia from $31.00 to $34.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Finally, Royal Bank of Canada upgraded shares of Phreesia from a “sector perform” rating to an “outperform” rating and increased their price objective for the stock from $24.00 to $32.00 in a report on Wednesday, January 8th. Thirteen analysts have rated the stock with a buy rating, According to MarketBeat, Phreesia presently has an average rating of “Buy” and a consensus price target of $31.15.

Insider Activity

In other news, Director Michael Weintraub sold 20,565 shares of the stock in a transaction dated Friday, December 13th. The shares were sold at an average price of $25.04, for a total transaction of $514,947.60. Following the transaction, the director now owns 242,827 shares of the company’s stock, valued at approximately $6,080,388.08. This trade represents a 7.81 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Amy Beth Vanduyn sold 1,311 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $26.61, for a total value of $34,885.71. Following the completion of the sale, the senior vice president now owns 115,633 shares of the company’s stock, valued at $3,076,994.13. This trade represents a 1.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 183,887 shares of company stock worth $5,146,862 over the last ninety days. Corporate insiders own 5.80% of the company’s stock.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.